Little Rock, Arkansas – The NuCressTM bone regeneration scaffold has received a 2018 TechConnect Defense Innovation award, as well as invitations to present at one of the nation’s premier defense events. Judged by a team of military and industry experts, the award is given to the top 15% of submissions to the Defense TechConnect Summit and Expo. According to the Expo, “Rankings are based on the potential positive impact the submitted technology will have for the warfighter and national security.”
“The recognition of our NuCress™ technologies by the Expo judges is gratifying and much appreciated. This conference represents the first public display of our products, technologies, and the medical needs that the NuCress™ scaffold may be able to help meet in the future,” says Sharon Ballard, NuShores’ CEO.
As one of the transformational technologies chosen for the Expo’s 2018 Innovation Showcase, the NuCressTM scaffold will be featured in the poster session, showcased at an exhibit, and highlighted in an invited presentation at the conference. Science and management team members from NuShores Biosciences LLC, the global, exclusive licensee of the scaffold technology, will present the NuCress™ scaffolds at these events.
This award comes just weeks after NuShores received $1.7 million in NIH SBIR Fast Track funding. This grant will enable NuShores and its project collaborators at Stony Brook University to explore the scaffold’s potential to improve regenerative treatment associated with dental implants. Long-time research collaborators at the University of Arkansas at Little Rock and the University of Tennessee,Knoxville, have supported the underlying scientific progress that enabled this new area of medical research.
About NuShores Biosciences LLC
NuShores’ vision is to improve the global quality of life for people suffering from bone loss. NuShores’ NuCress™ scaffold offers many benefits not achieved by currently marketed bone regeneration products, promising better treatment outcomes to millions with severe bone injuries. Studies suggest that this licensed, patented technology will deliver improved solutions for bone regeneration while cutting healthcare costs, lowering treatment risks, and reducing healing time.
Acknowledgements
Research described in this press release is supported by the National Center for Dental and Craniofacial Research of the National Institutes of Health under award number 1R44DE028213-01.
To learn more about this announcement, please contact
Sharon C. Ballard, CEO
NuShores Biosciences LLC
sharon@nushores.com
